# A Multicentre Study to Evaluate the Safety and Efficacy of AD 923 in Comparison to MSIR for the Treatment of CBP in Subjects

> **NCT00635063** · PHASE3 · TERMINATED · sponsor: **Sosei** · enrollment: 150 (estimated)

## Conditions studied

- Cancer
- Pain

## Interventions

- **DRUG:** AD 923

## Key facts

- **NCT ID:** NCT00635063
- **Lead sponsor:** Sosei
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 150 (ESTIMATED)
- **Why stopped:** Termination is due to a combination of a device defect potentially impacting the quality of the AD 923 IMP and a major change in corporate strategy.
- **Last updated:** 2008-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635063, "A Multicentre Study to Evaluate the Safety and Efficacy of AD 923 in Comparison to MSIR for the Treatment of CBP in Subjects". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00635063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*